Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Behringer, K.
Right arrow Articles by Engert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Behringer, K.
Right arrow Articles by Engert, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1079-1085, 2004
© 2004 European Society for Medical Oncology

Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group

Background: Long-term survivors of successfully treated Hodgkin's disease (HD) are at risk for late complications. Among these, secondary solid tumors are most serious because they are often fatal. The aim of this retrospective analysis was to assess the incidence, relative risk and risk factors of secondary solid tumors in HD patients registered in the database of the German Hodgkin Lymphoma Study Group (GHSG).

Patients and methods: From 1983 to 1998, the GHSG conducted three generations of clinical trials for early, intermediate and advanced stage HD (HD1–HD9) involving a total of 5367 patients. Data on incidence, risk factors and relative risk were updated in March 2003.

Results: A total of 127 patients with secondary solid tumors were identified. Among these, lung cancer (23.6%), colorectal cancer (20.5%) and breast cancer (10.2%) were the most frequent. After a median follow-up of 72 months the cumulative risk of developing a solid tumor was 2%, with an overall relative risk (RR) of 2.4 (lung cancer, 3.8; colorectal cancer, 3.2; breast cancer, 1.9). For most patients (n=67; 52.8%) developing a secondary solid tumor, treatment modality consisted of chemotherapy combined with radiotherapy in extended field technique (RR = 3.3).

Conclusions: With a median follow-up of 72 months, there were 127 patients developing solid tumors out of a total of 5367 HD patients treated in the GHSG studies HD1–HD9. The cumulative risk of 2% is expected to increase over time due to the rather short median observation time and slow progression of solid malignancies.

K. Behringer1,*, A. Josting1, P. Schiller1, H. T. Eich2, H. Bredenfeld1, V. Diehl1 and A. Engert1

1 First Department of Internal Medicine, University Hospital Cologne and the German Hodgkin Lymphoma Study Group (GHSG); 2 Department of Radiation Oncology, University of Cologne, Germany

*Correspondence to: Dr K. Behringer, First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany. Tel: +49-221-473558; Fax: +49-221-476311; Email: karolin.behringer{at}biometrie.uni-koeln.de

Key words: Hodgkin's lymphoma, risk factors, secondary solid tumors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am Soc Clin Oncol Ed BookHome page
A. K. Ng
Second Cancers after Hodgkin's Lymphoma: Long-term Risks
ASCO Educational Book, January 1, 2008; 2008(1): 418 - 422.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Sieniawski, T. Reineke, L. Nogova, A. Josting, B. Pfistner, V. Diehl, and A. Engert
Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)
Blood, January 1, 2008; 111(1): 71 - 76.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Drakos, A. Thomaides, L. J. Medeiros, J. Li, V. Leventaki, M. Konopleva, M. Andreeff, and G. Z. Rassidakis
Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma
Clin. Cancer Res., June 1, 2007; 13(11): 3380 - 3387.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B Klimm, H. Eich, H Haverkamp, A Lohri, P Koch, F Boissevain, G Trenn, P Worst, E Duhmke, R. Muller, et al.
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
Ann. Onc., February 1, 2007; 18(2): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Ferme, N. Mounier, O. Casasnovas, P. Brice, M. Divine, A. Sonet, F. Bouafia, A. Bastard-Stamatoullas, D. Bordessoule, L. Voillat, et al.
Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Blood, June 15, 2006; 107(12): 4636 - 4642.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Klimm, T. Reineke, H. Haverkamp, K. Behringer, H. T. Eich, A. Josting, B. Pfistner, V. Diehl, and A. Engert
Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study Group
J. Clin. Oncol., November 1, 2005; 23(31): 8003 - 8011.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Utkan, A. Buyukcelik, and B. Yalcin
Solid tumors in patients treated for Hodgkin's disease
Ann. Onc., December 1, 2004; 15(12): 1848 - 1849.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.